# Developmental Therapeutics Program

## One Dose Mean Graph

| | | |
|---|---|---|
| **NSC:** 766295 / 1 | **Conc:** 1.00E-5 Molar | **Test Date:** Jul 30, 2012 |
| **Experiment ID:** 1207OS20 | | **Report Date:** Oct 12, 2012 |

| Panel/Cell Line | Growth Percent |
|---|---|
| Leukemia | |
| CCRF-CEM | 70.48 |
| HL-60(TB) | 62.05 |
| K-562 | 76.80 |
| MOLT-4 | 69.42 |
| RPMI-8226 | 57.67 |
| SR | 22.82 |
| Non-Small Cell Lung Cancer | |
| A549/ATCC | 63.04 |
| HOP-62 | 79.19 |
| NCI-H226 | 57.91 |
| NCI-H23 | 90.90 |
| NCI-H322M | 90.42 |
| NCI-H460 | 63.22 |
| NCI-H522 | 53.48 |
| Colon Cancer | |
| COLO 205 | 113.82 |
| HCC-2998 | 118.14 |
| HCT-116 | 81.68 |
| HCT-15 | 75.15 |
| HT29 | 111.29 |
| SW-620 | 94.53 |
| CNS Cancer | |
| SF-268 | 64.08 |
| SF-295 | 76.18 |
| SF-539 | 75.06 |
| SNB-19 | 79.86 |
| SNB-75 | 35.51 |
| U251 | 60.57 |
| Melanoma | |
| LOX IMVI | 74.98 |
| MALME-3M | 68.16 |
| M14 | 86.65 |
| MDA-MB-435 | 77.42 |
| SK-MEL-2 | 84.66 |
| SK-MEL-28 | 73.46 |
| SK-MEL-5 | 56.75 |
| UACC-257 | 89.70 |
| UACC-62 | 82.50 |
| Ovarian Cancer | |
| IGROV1 | 75.49 |
| OVCAR-3 | 86.48 |
| OVCAR-4 | 64.10 |
| OVCAR-5 | 86.56 |
| OVCAR-8 | 58.54 |
| NCI/ADR-RES | 64.67 |
| SK-OV-3 | 79.77 |
| Renal Cancer | |
| 786-0 | 74.91 |
| A498 | -9.39 |
| ACHN | 67.58 |
| CAKI-1 | 76.70 |
| RXF 393 | 66.32 |
| SN12C | 63.51 |
| TK-10 | 56.43 |
| UO-31 | 44.29 |
| Prostate Cancer | |
| PC-3 | 44.41 |
| DU-145 | 76.14 |
| Breast Cancer | |
| MCF7 | 66.53 |
| MDA-MB-231/ATCC | 70.50 |
| HS 578T | 65.25 |
| BT-549 | 65.10 |
| T-47D | 48.71 |
| MDA-MB-468 | 61.44 |
| Mean | 70.03 |
| Delta | 79.42 |
| Range | 127.53 |

**Mean Growth Percent - Growth Percent**